Fig. 1

ARID1A regulates the expression of DUSP4. a Differential expression of genes using RNA sequencing between human endometrial epithelial cells (hEM3-Con) and ARID1A knockout cells (hEM3 ARID1A−/−). Prominent genes are shown in the graph in purple. b Fold changes of the indicated genes of interest discovered by RNA-seq are plotted. c Representative Western blot validating the indicated proteins in hEM3-Con and hEM3 ARID1A knockout (ARID1A−/−) cells. d Representative Western blot validation of DUSP4 downregulation after ARID1A loss in multiple isogenic cells. e The University of California Santa Cruz (UCSC) genome browser view of the occupancy of H3K9me3, H3K27me3, H3K9Ac, and H3K27Ac in the regulatory region of DUSP4. ChIP-seq tracks show peaks of methylation and acetylation histone marks on the DUSP4 promoter and enhancer regions. Dotted rectangles indicate locations of important binding events. The right dotted rectangle shows the DUSP4 enhancer region, whereas the left dotted rectangle indicates the promoter region. The arrow underneath the graph indicates the orientation of DUSP4 transcription. f qRT‒PCR validation of DUSP4 downregulation in ARID1A-deficient hEM3 cells (ARID1A−/−) compared to isogenic control cells. Measurement of ARID1A and TGFBR2 mRNA levels was performed as additional controls. TGFBR2 was previously reported as a direct target of ARID1A [15]. g DUSP4 mRNA expression across different stages of endometrial cancer (UCEC) with a sample size of N = 174. The dotted line indicates a decrease in DUSP4 expression as the disease progresses, (accessed via: http://gepia2.cancer-pku.cn/#analysis). h Kaplan‒Meier plot showing overall survival (OS) and i relapse-free survival (RFS) based on DUSP4 mRNA expression levels in UCEC (uterine corpus endometrial carcinoma) patients with a sample size of 543, (Accessed via: http://kmplot.com/analysis/index.php?p=service)